Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models

• Francesca Barone,
• Paul P Tak,
• Sean Lawler,
• James A Lederer,
• Marilin S Koch,
• Mykola Zdioruk,
• Michal O Nowicki,
• Alec M Griffith,
• Estuardo Aguilar,
• Laura K Aguilar,
• Brian W Guzik,
• E Antonio Chiocca

Affiliations

Francesca Barone

6 RRG, Institute of Inflamation and Ageing, University of Birmingham, Birmingham, UK, UK

Paul P Tak

1 Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Sean Lawler

1Brigham and Women’s Hospital, Boston, MA, USA

James A Lederer

1Brigham and Women’s Hospital and Harvard Medical School, USA

Marilin S Koch

Department of Neurosurgery, Brigham and Women`s Hospital, Boston, Massachusetts, USA

Mykola Zdioruk

Department of Neurosurgery, Brigham and Women`s Hospital, Boston, Massachusetts, USA

Michal O Nowicki

Department of Neurosurgery, Brigham and Women`s Hospital, Boston, Massachusetts, USA

Alec M Griffith

Harvard Medical School, Boston, Massachusetts, USA

Estuardo Aguilar

Candel Therapeutics, Needham, Massachusetts, USA

Laura K Aguilar

Candel Therapeutics, Needham, Massachusetts, USA

Brian W Guzik

Candel Therapeutics, Needham, Massachusetts, USA

E Antonio Chiocca

Department of Neurosurgery, Brigham and Women`s Hospital, Boston, Massachusetts, USA